[92] [93] Personal life As of 2026Florida
We recommend discussing NAION risk with healthcare providers before starting GLP-1 therapy
they should not be directly compared with results from trials of other agents, as differences in trial design, population, background therapy, and follow-up duration make cross-trial comparisons unreliable
Overall, through an integrated analysis of the phenotypic and metabolic characteristics in our nematode model, we clearly show a functional effect of all variants
These interim results focus solely on histological endpoints
You may have health issues that interfere with your bodys ability to absorb the nutrient, you might not be getting enough in your diet, or you could be taking drugs that lower the levels of B12 in your body